Latest Cutter Capital Management, LP Stock Portfolio
Cutter Capital Management, LP Performance:
2025 Q1: -0.08%YTD: -0.08%2024: -1.96%
Performance for 2025 Q1 is -0.08%, and YTD is -0.08%, and 2024 is -1.96%.
About Cutter Capital Management, LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Cutter Capital Management, LP reported an equity portfolio of $229.6 Millions as of 31 Mar, 2025.
The top stock holdings of Cutter Capital Management, LP are BMY, AMGN, BIIB. The fund has invested 7.8% of it's portfolio in BRISTOL-MYERS SQUIBB CO and 6.8% of portfolio in AMGEN INC.
The fund managers got completely rid off REGENERON PHARMACEUTICALS (REGN), JOHNSON & JOHNSON (JNJ) and ABBVIE INC (ABBV) stocks. They significantly reduced their stock positions in ROYALTY PHARMA PLC (RPRX), NEWAMSTERDAM PHARMA COMPANY (NAMS) and BRIDGEBIO PHARMA INC (BBIO). Cutter Capital Management, LP opened new stock positions in BRISTOL-MYERS SQUIBB CO (BMY), BIOGEN INC (BIIB) and ELI LILLY & CO (LLY). The fund showed a lot of confidence in some stocks as they added substantially to CENTESSA PHARMACEUTICALS PLC (CNTA), TARSUS PHARMACEUTICALS INC (TARS) and PERRIGO CO PLC (PRGO).
The top stock holdings of Cutter Capital Management, LP are BMY, AMGN, BIIB. The fund has invested 7.8% of it's portfolio in BRISTOL-MYERS SQUIBB CO and 6.8% of portfolio in AMGEN INC.
The fund managers got completely rid off REGENERON PHARMACEUTICALS (REGN), JOHNSON & JOHNSON (JNJ) and ABBVIE INC (ABBV) stocks. They significantly reduced their stock positions in ROYALTY PHARMA PLC (RPRX), NEWAMSTERDAM PHARMA COMPANY (NAMS) and BRIDGEBIO PHARMA INC (BBIO). Cutter Capital Management, LP opened new stock positions in BRISTOL-MYERS SQUIBB CO (BMY), BIOGEN INC (BIIB) and ELI LILLY & CO (LLY). The fund showed a lot of confidence in some stocks as they added substantially to CENTESSA PHARMACEUTICALS PLC (CNTA), TARSUS PHARMACEUTICALS INC (TARS) and PERRIGO CO PLC (PRGO).
Cutter Capital Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Cutter Capital Management, LP made a return of -0.08% in the last quarter. In trailing 12 months, it's portfolio return was -0.84%.
New Buys
| Ticker | $ Bought |
|---|---|
| bristol-myers squibb co | 17,992,000 |
| biogen inc | 15,531,300 |
| eli lilly & co | 14,866,400 |
| roivant sciences ltd | 13,117,000 |
| verona pharma plc | 10,158,400 |
| madrigal pharmaceuticals inc | 7,949,520 |
| summit therapeutics inc | 7,716,000 |
| halozyme therapeutics inc | 7,657,200 |
New stocks bought by Cutter Capital Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| centessa pharmaceuticals plc | 184 |
| tarsus pharmaceuticals inc | 82.22 |
| perrigo co plc | 62.81 |
| teva pharmaceutical inds ltd | 37.09 |
| amgen inc | 31.27 |
Additions to existing portfolio by Cutter Capital Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| royalty pharma plc | -53.34 |
| newamsterdam pharma company | -34.41 |
| bridgebio pharma inc | -30.28 |
| agios pharmaceuticals inc | -21.97 |
| insmed inc | -11.62 |
| ultragenyx pharmaceutical in | -6.76 |
Cutter Capital Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| viridian therapeutics inc | -12,051,700 |
| akero therapeutics inc | -6,398,600 |
| vera therapeutics inc | -8,994,910 |
| moderna inc | -8,212,050 |
| neumora therapeutics inc. | -1,590,000 |
| johnson & johnson | -20,474,100 |
| sarepta therapeutics inc | -15,108,300 |
| janux therapeutics inc | -6,424,800 |
Cutter Capital Management, LP got rid off the above stocks
Sector Distribution
Cutter Capital Management, LP has about 100% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 100 |
Market Cap. Distribution
Cutter Capital Management, LP has about 44.3% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 40.7 |
| LARGE-CAP | 37.8 |
| SMALL-CAP | 13.1 |
| MEGA-CAP | 6.5 |
| UNALLOCATED | 2 |
Stocks belong to which Index?
About 63.3% of the stocks held by Cutter Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 36.8 |
| RUSSELL 2000 | 35.4 |
| S&P 500 | 27.9 |
Cutter Capital Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Cutter Capital Management, LP
Cutter Capital Management, LP has 21 stocks in it's portfolio. About 62.8% of the portfolio is in top 10 stocks. TEVA proved to be the most loss making stock for the portfolio. RPRX was the most profitable stock for Cutter Capital Management, LP last quarter.
Last Reported on: 15 May, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABBV | abbvie inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AGIO | agios pharmaceuticals inc | 3.00 | 235,350 | 6,895,760 | reduced | -21.97 | ||
| AKRO | akero therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AMGN | amgen inc | 6.78 | 50,000 | 15,577,500 | added | 31.27 | ||
| BBIO | bridgebio pharma inc | 5.88 | 390,644 | 13,504,600 | reduced | -30.28 | ||
| BIIB | biogen inc | 6.76 | 113,500 | 15,531,300 | new | |||
| BMY | bristol-myers squibb co | 7.84 | 295,000 | 17,992,000 | new | |||
| CNTA | centessa pharmaceuticals plc | 2.62 | 418,127 | 6,012,670 | added | 184 | ||
| CYTK | cytokinetics inc | 3.06 | 175,000 | 7,033,250 | new | |||
| HALO | halozyme therapeutics inc | 3.33 | 120,000 | 7,657,200 | new | |||
| INSM | insmed inc | 6.19 | 186,384 | 14,219,200 | reduced | -11.62 | ||
| JANX | janux therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| JNJ | johnson & johnson | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| LLY | eli lilly & co | 6.47 | 18,000 | 14,866,400 | new | |||
| MDGL | madrigal pharmaceuticals inc | 3.46 | 24,000 | 7,949,520 | new | |||
| MRNA | moderna inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NAMS | newamsterdam pharma company | 1.97 | 221,152 | 4,526,980 | reduced | -34.41 | ||
| PRGO | perrigo co plc | 5.86 | 479,517 | 13,445,700 | added | 62.81 | ||
| RARE | ultragenyx pharmaceutical in | 5.98 | 379,303 | 13,734,600 | reduced | -6.76 | ||
| RCUS | arcus biosciences inc | 2.50 | 731,818 | 5,744,770 | new | |||